Cargando…
Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies
This study tested the anticoagulant effect of cyclodextrin (CD) hyper-branched-based polymers (HBCD-Pols). These polymers were synthesized and tested for their coagulant characteristics in vitro and in vivo. Due to their polymeric structure and anionic nature, the polymers can chelate Ca(2+), reduci...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774232/ https://www.ncbi.nlm.nih.gov/pubmed/36550971 http://dx.doi.org/10.3390/bioengineering9120765 |
_version_ | 1784855357412081664 |
---|---|
author | Monfared, Yousef Khazaei Mahmoudian, Mohammad Hoti, Gjylije Bisericaru, Daniel Mihai Caldera, Fabrizio Cavalli, Roberta Zakeri-Milani, Parvin Matencio, Adrián Trotta, Francesco |
author_facet | Monfared, Yousef Khazaei Mahmoudian, Mohammad Hoti, Gjylije Bisericaru, Daniel Mihai Caldera, Fabrizio Cavalli, Roberta Zakeri-Milani, Parvin Matencio, Adrián Trotta, Francesco |
author_sort | Monfared, Yousef Khazaei |
collection | PubMed |
description | This study tested the anticoagulant effect of cyclodextrin (CD) hyper-branched-based polymers (HBCD-Pols). These polymers were synthesized and tested for their coagulant characteristics in vitro and in vivo. Due to their polymeric structure and anionic nature, the polymers can chelate Ca(2+), reducing the free quantity in blood. HBCD-Pol increased the blood clotting time, PT, and aPTT 3.5 times over the control, showing a better effect than even ethylenediaminetetraacetic acid (EDTA), as occured with recalcification time as well. A titration of HBCD-Pol and EDTA showed exciting differences in the ability to complex Ca(2+) between both materials. Before executing in vivo studies, a hemocompatibility study was carried out with less than 5% red blood cell hemolysis. The fibrinogen consumption and bleeding time were analyzed in vivo. The fibrinogen was considerably decreased in the presence of HBCD-Pol in a higher grade than EDTA, while the bleeding time was longer with HBCD-Pols. The results demonstrate that the anticoagulant effect of this HBCD-Pol opens novel therapy possibilities due to the possible transport of drugs in this carrier. This would give combinatorial effects and a potential novel anticoagulant therapy with HBCD-Pol per se. |
format | Online Article Text |
id | pubmed-9774232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97742322022-12-23 Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies Monfared, Yousef Khazaei Mahmoudian, Mohammad Hoti, Gjylije Bisericaru, Daniel Mihai Caldera, Fabrizio Cavalli, Roberta Zakeri-Milani, Parvin Matencio, Adrián Trotta, Francesco Bioengineering (Basel) Article This study tested the anticoagulant effect of cyclodextrin (CD) hyper-branched-based polymers (HBCD-Pols). These polymers were synthesized and tested for their coagulant characteristics in vitro and in vivo. Due to their polymeric structure and anionic nature, the polymers can chelate Ca(2+), reducing the free quantity in blood. HBCD-Pol increased the blood clotting time, PT, and aPTT 3.5 times over the control, showing a better effect than even ethylenediaminetetraacetic acid (EDTA), as occured with recalcification time as well. A titration of HBCD-Pol and EDTA showed exciting differences in the ability to complex Ca(2+) between both materials. Before executing in vivo studies, a hemocompatibility study was carried out with less than 5% red blood cell hemolysis. The fibrinogen consumption and bleeding time were analyzed in vivo. The fibrinogen was considerably decreased in the presence of HBCD-Pol in a higher grade than EDTA, while the bleeding time was longer with HBCD-Pols. The results demonstrate that the anticoagulant effect of this HBCD-Pol opens novel therapy possibilities due to the possible transport of drugs in this carrier. This would give combinatorial effects and a potential novel anticoagulant therapy with HBCD-Pol per se. MDPI 2022-12-04 /pmc/articles/PMC9774232/ /pubmed/36550971 http://dx.doi.org/10.3390/bioengineering9120765 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Monfared, Yousef Khazaei Mahmoudian, Mohammad Hoti, Gjylije Bisericaru, Daniel Mihai Caldera, Fabrizio Cavalli, Roberta Zakeri-Milani, Parvin Matencio, Adrián Trotta, Francesco Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies |
title | Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies |
title_full | Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies |
title_fullStr | Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies |
title_full_unstemmed | Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies |
title_short | Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies |
title_sort | hyper-branched cyclodextrin-based polymers as anticoagulant agents: in vitro and in vivo studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774232/ https://www.ncbi.nlm.nih.gov/pubmed/36550971 http://dx.doi.org/10.3390/bioengineering9120765 |
work_keys_str_mv | AT monfaredyousefkhazaei hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT mahmoudianmohammad hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT hotigjylije hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT bisericarudanielmihai hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT calderafabrizio hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT cavalliroberta hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT zakerimilaniparvin hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT matencioadrian hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies AT trottafrancesco hyperbranchedcyclodextrinbasedpolymersasanticoagulantagentsinvitroandinvivostudies |